Today the use of pneumatic tourniquet is commonly accepted in total knee arthroplasty (TKA) to reduce perioperative blood loss. There are a few prospective randomised and nonrandomised studies that compare the effect of tourniquet release timing in cementless or cemented unilateral TKA. However, many of these studies show an inadequate reporting and methodology. This randomized prospective study was designed to investigate the efficiency of tourniquet release timing in preventing perioperative blood loss in a simultaneous bilateral TKA study design. To our knowledge, this is the first study of its kind, in which the effect of tourniquet release timing on perioperative blood loss was investigated in simultaneous bilateral cemented TKA. In 20 patients (40 knees) one knee was operated with tourniquet release and hemostasis before wound closure, and the other knee with tourniquet release after wound closure and pressure dressing. To determine the order of tourniquet release technique for simultaneous bilateral TKA, patients were randomized in two groups: ‘Group A’ first knee with tourniquet release and hemostasis before wound closure, and ‘Group B’ second knee with tourniquet release and hemostasis before wound closure. The blood loss was recorded 48 hours postoperative for each technique. We found no significant difference in total blood loss between both techniques (p =.930), but a significant difference in operating time (p =.035). There were no postoperative complications at a follow-up of 6 month. Other studies report an increase the blood loss in early tourniquet release and an increase the risk of early postoperative complications in deflation of tourniquet after wound closure. In this study we found no significant difference in perioperative blood loss and no increase of postoperative complications. Therefore, we recommend a tourniquet release after wound closure to reduce the duration of TKA procedure and to avoid possible risks of extended anaesthesia

Introduction: Periacetabular osteotomy (PAO) is a major orthopaedic surgical procedure which may be associated with a significant blood loss and complications. We have compared the perioperative blood loss and complications using two different approaches – The modified iliofemoral (MI) and ilioinguinal (II) for PAO. MATERIALS AND Methods: 92 PAO’s in 80 patients (54 females; 26 males), with dysplastic hip joints, operated at Odense University Hospital with the Bernese method, between 2003 and Feb. 2006, using the MI or the II were included. The MI include no release of the tensor fascia lata, sartorius or rectus femoris. The procedures were reviewed with primary focus on perioperative blood loss, length of surgery and neurovascular complications. Patients who underwent combined surgery of acetabulum and femur were excluded. Data are presented as mean with 95% confidence interval (CI) in brackets. Results: The MI approach was used in 65 and the II in 27 PAO’s. Average time for surgery in the MI group was 88 min (95% CI: 83–94) and in the II group 106 min (95% CI: 97–114), (P=0.0007). The intraoperative blood loss in the MI group was 571 ml (95% CI: 489–654) compared with 518 ml (95% CI: 387–649) in the II group (P=0.49). However, postoperatively, the hemoglobin concentration was 7.1 (95% CI: 6.9–7.3) in the MI group compared with 6.6 (95% CI: 6.1–6.8) in the II group (P=0.002). The MI group had 1 case of major arterial bleeding, however no blood transfusion. The II group had 2 cases of arterial thrombosis and one transient sciatic nerve palsy. One patient received blood transfusion. CONCLUSION: In this study, the MI approach was proved to be significantly faster than the II, however no significant difference was found in intraoperative blood loss, but the hemoglobin fell significantly less in the MI compared with the II group. The II approach was associated with 3 major complication compared with one in the MI

In modern surgery, one main goal is to reduce perioperative and postoperative transfusion need. The haemostatic disorders, the patients’ gender and the type of the operation seems to predict the blood loss in orthopaedic surgery. It has been reported recently, an association of the Factor V Leiden mutation and with a lower rate of intra-partum blood loss,. Purpose: The aim of our study was to evaluate if there is an association between blood loss and pro c global system in orthopaedic operations. Pro C Global system is influenced by FRO C, PRO S, APC resistance (FV Leiden) and FV111. Materials and methods: We studied 42 patients, 31 women and 11 men, between 22–86 years old, who were operated in our hospital. 19 with total knee arthroplasty, 11 with total hip arthroplasty, 11 with fractures and 1 patient with amputation of -the lower leg. The blood loss for each patient was calculated according the Mercurialli formula: Total blood loss: total blood volume x (Ht preop-Ht day 5 postop)+ml of RBC transfused. The total blood loss was expressed in terms of percentage of total blood volume and defined as relative blood loss. Patients were divided into two groups with high and low relative blood loss, according the median value of the relative blood loss. Pro C global values was monitored in all patients pre-operatively on a BCT analyzer (Dade Behring). Values > 0.8 are considered normal. Results: The median value of relative blood loss was 15,05%. 21 patients were below this level and considered to have low relative blood loss. 21 patients were above this level and considered to have high relative blood loss. 18 patients had pro C Global values < 0.8 and 24 patients had Pro C Global > 0.8. Patients with low relative blood loss tend to show lower Pro C Global values than patients with high relative blood loss. (0,87 versus 0.90, p= 0.7 NS) without statistical difference. Conclusions: In this study the Pro C global system does not seems to predict perioperative blood loss in patients with orthopaedic surgery and so it is useless to be monitored preoperatively

Total joint arthroplasty is one of the most common procedures performed in orthopaedic surgery. Over 600,000 total hip and total knee replacements are performed in the United States each year. At our 550 bed tertiary care facility, 437 total knee arthroplasties were performed in 2010 and 426 in 2011. Tranexamic acid is an antifibrinolyic synthetic derivative of aminocaproic acid used to prevent hemorrhage in patients undergoing surgical procedures. Several studies show decreased blood loss in patients receiving both intravenous and topical tranexamic acid. Beginning in 2011, our surgeons began using topical tranexamic acid in an irrigation solution of 3 grams in 100 mL of normal saline after implant placement and prior to closure of the incision. Our study is a retrospective review comparing patients receiving total knee arthroplasties before and after the institution of tranexamic acid. The purpose of our study was to assess estimated perioperative blood loss, determining the cost effectiveness of using tranexamic acid while comparing adverse effects of using topical tranexamic acid in total knee arthroplasty. Our study includes 683 primary total knees, 373 that received did not receive topical tranexamic acid and 310 that did, from January 1, 2010 to October 31, 2011. There were no demographic differences between the 2 groups. Topical tranexamic acid significantly (p<0.0001) decreased blood loss in patients receiving primary total knee arthroplasties. There were no differences between groups in thromboembolic events or joint infections. Tranexamic acid significantly (p<0.0001) decreased both blood bank cost and total cost of stay resulting in nearly $1,500 savings per patient to our institution

Introduction: Besides other techniques to reduce blood loss, the use of pneumatic tourniquet is commonly accepted in total knee arthroplasty (TKA). Furthermore it is used to maintain a clean and dry operative field to improve visualization, to use a better cementing technique, and to reduce operating time. The time of tourniquet release is discussed controversially in literature. However, there are only a few prospective randomised studies that compared the effect of timing of tourniquet release in cementless or cemented TKA. To our knowledge, this is the first study that investigated the influence of tourniquet release on blood loss in a randomized prospective study in simultaneous bilateral cemented TKA. Methods: 20 patients (40 knees) underwent simultaneous bilateral cemented TKA with the cemented Triathlon Knee System (Stryker) between February and May 2006. The mean age of the patients was 67 years (67+/−11 years). 7 males and 13 females were treated with TKA (mean tourniquet pressure: 282.5+/−33.5 mm Hg). In 20 patients one knee was operated with tourniquet release and hemostasis before wound closure (“Technique A”), and the other knee with tourniquet release after wound closure and pressure dressing (“Technique B”). To determine the order of tourniquet release technique in simultaneous bilateral TKA, the patients were randomized in two groups: “Group A” (20 knees) first knee with tourniquet release and hemostasis before wound closure, and “Group B” (20 knees) second knee with tourniquet release and hemostasis before wound closure. The patients were given low molecular weight heparin and a leg dressing to prevent deep vein thrombosis. The blood loss was monitored two days after surgery till removal of the wound drains. Results: We found no significant difference in total blood loss between “Technique A” (753+/−390 ml) and “Technique B” (760+/−343 ml) (p=.930). Furthermore there was no significant difference in total blood loss between both techniques after randomizing in “Group A” (“Technique A” 653+/−398 ml; “Technique B” 686+/−267 ml; p=.751) and “Group B” (“Technique A” 854+/−374 ml; “Technique B” 834+/−406 ml; p=.861). However, the operating time showed a significant difference between “Technique A” (58+/−18 minutes) and “Technique B” (51+/−17 minutes) (p=.035). Discussion: In this study we compared the effect of timing of tourniquet release on perioperative blood loss in a randomized prospective study in simultaneous bilateral cemented TKA. Our results showed no significant difference of blood loss but a significant difference of operation time. Therefore, we recommend a tourniquet release after wound closure to reduce operating time and to minimize the risk of peri- and postoperative complications at approximately similarly blood loss between both techniques

Blood loss during the perioperative period of total joint arthroplasty has been well described in the literature. Despite numerous advances, allogeneic transfusion rates are still reported as high as 50%. Often the literature focuses on one area or mechanism of blood loss prevention but this article focuses on a multimodal approach to blood loss prevention including preoperative optimization, intraoperative technique, and postoperative management. Hemoglobin drop and transfusion rates were retrospectively reviewed for 134 control patients undergoing total knee arthroplasty (TKA) in three groups. Group 1 included low risk patients (Hb >14 g/dl), Group 2 included intermediate risk patients (Hb 13-14 g/dl) utilizing reinfusion drain and preoperative autologous blood donation, and Group 3 included high risk (Hgb <13) patients treated with preoperative erythropoietin (EPO). These controls were then compared to two groups of patients undergoing minimally invasive total knee arthroplasty (MIS TKA). Group 4 included 20 consecutive patients undergoing MIS TKA with intraoperative injection of lidocaine and epinephrine along the arthrotomy site. Group 5 included 22 consecutive patients treated with similar technique plus the additional intraoperative use of a bipolar sealer device. The combined utilization of MIS TKA, epinephrine, and bipolar sealer minimized hemoglobin drop (2.74 (Std Dev 0.77) vs 3.29 (SD 1.05) g/dl, p= 0.01) and total blood transfusions (0.05 (SD 0.21) vs 0.86 (SD 0.63) units, p< 0.01) compared with the traditional TKA approach for high risk patients using reinfusion drain and preoperative autologous donation (Group 2). This series demonstrates how a busy knee practice minimizes hemoglobin drop and transfusion requirements with preoperative optimization of high risk patients utilizing EPO, minimally invasive technique, intraoperative hemostasis obtained with epinephering injection, use of a bipolar sealer, and postoperative management with a reinfusion drain.

Aims. The aim of this study was to examine perioperative blood transfusion practice, and associations with clinical outcomes, in a national cohort of hip fracture patients. Methods. A retrospective cohort study was undertaken using linked data from the Scottish Hip Fracture Audit and the Scottish National Blood Transfusion Service between May 2016 and December 2020. All patients aged ≥ 50 years admitted to a Scottish hospital with a hip fracture were included. Assessment of the factors independently associated with red blood cell transfusion (RBCT) during admission was performed, alongside determination of the association between RBCT and hip fracture outcomes. Results. A total of 23,266 individual patient records from 18 hospitals were included. The overall rate of blood transfusion during admission was 28.7% (n = 6,685). There was inter-hospital variation in transfusion rate, ranging from 16.6% to 37.4%. Independent perioperative factors significantly associated with RBCT included older age (90 to 94 years, odds ratio (OR) 3.04 (95% confidence interval (CI) 2.28 to 4.04); p < 0.001), intramedullary fixation (OR 7.15 (95% CI 6.50 to 7.86); p < 0.001), and sliding hip screw constructs (OR 2.34 (95% CI 2.19 to 2.50); p < 0.001). Blood transfusion during admission was significantly associated with higher rates of 30-day mortality (OR 1.35 (95% CI 1.19 to 1.53); p < 0.001) and 60-day mortality (OR 1.54 (95% CI 1.43 to 1.67); p < 0.001), as well as delays to postoperative mobilization, higher likelihood of not returning to their home, and longer length of stay. Conclusion. Blood transfusion after hip fracture was common, although practice varied nationally. RBCT is associated with adverse outcomes, which is most likely a reflection of perioperative anaemia, rather than any causal effect. Use of RBCT does not appear to reverse this effect, highlighting the importance of perioperative blood loss reduction. Cite this article: Bone Joint J 2022;104-B(11):1266–1272

Aims. Our objective was to conduct a systematic review and meta-analysis, to establish whether differences arise in clinical outcomes between autologous and synthetic bone grafts in the operative management of tibial plateau fractures. Methods. A structured search of MEDLINE, EMBASE, the online archives of Bone & Joint Publishing, and CENTRAL databases from inception until 28 July 2021 was performed. Randomized, controlled, clinical trials that compared autologous and synthetic bone grafts in tibial plateau fractures were included. Preclinical studies, clinical studies in paediatric patients, pathological fractures, fracture nonunion, or chondral defects were excluded. Outcome data were assessed using the Risk of Bias 2 (ROB2) framework and synthesized in random-effect meta-analysis. The Preferred Reported Items for Systematic Review and Meta-Analyses guidance was followed throughout. Results. Six studies involving 353 fractures were identified from 3,078 records. Following ROB2 assessment, five studies (representing 338 fractures) were appropriate for meta-analysis. Primary outcomes showed non-significant reductions in articular depression at immediate postoperative (mean difference -0.45 mm, p = 0.25, 95%confidence interval (CI) -1.21 to 0.31, I. 2. = 0%) and long-term (> six months, standard mean difference -0.56, p = 0.09, 95% CI -1.20 to 0.08, I. 2. = 73%) follow-up in synthetic bone grafts. Secondary outcomes included mechanical alignment, limb functionality, and defect site pain at long-term follow-up, perioperative blood loss, duration of surgery, occurrence of surgical site infections, and secondary surgery. Mean blood loss was lower (90.08 ml, p < 0.001, 95% CI 41.49 to 138.67) and surgery was shorter (16.17 minutes, p = 0.04, 95% CI 0.39 to 31.94) in synthetic treatment groups. All other secondary measures were statistically comparable. Conclusion. All studies reported similar methodologies and patient populations; however, imprecision may have arisen through performance variation. These findings supersede previous literature and indicate that, despite perceived biological advantages, autologous bone grafting does not demonstrate superiority to synthetic grafts. When selecting a void filler, surgeons should consider patient comorbidity, environmental and societal factors in provision, and perioperative and postoperative care provision. Cite this article: Bone Jt Open 2022;3(3):218–228

Aims. The purpose of this study was to examine the efficacy and safety of carbazochrome sodium sulfonate (CSS) combined with tranexamic acid (TXA) on blood loss and inflammatory responses after primary total hip arthroplasty (THA), and to investigate the influence of different administration methods of CSS on perioperative blood loss during THA. Methods. This study is a randomized controlled trial involving 200 patients undergoing primary unilateral THA. A total of 200 patients treated with intravenous TXA were randomly assigned to group A (combined intravenous and topical CSS), group B (topical CSS), group C (intravenous CSS), or group D (placebo). Results. Mean total blood loss (TBL) in groups A (605.0 ml (SD 235.9)), B (790.9 ml (SD 280.7)), and C (844.8 ml (SD 248.1)) were lower than in group D (1,064.9 ml (SD 318.3), p < 0.001). We also found that compared with group D, biomarker level of inflammation, transfusion rate, pain score, and hip range of motion at discharge in groups A, B, and C were significantly improved. There were no differences among the four groups in terms of intraoperative blood loss (IBL), intramuscular venous thrombosis (IMVT), and length of hospital stay (LOS). Conclusion. The combined application of CSS and TXA is more effective than TXA alone in reducing perioperative blood loss and transfusion rates, inflammatory response, and postoperative hip pain, results in better early hip flexion following THA, and did not increase the associated venous thromboembolism (VTE) events. Intravenous combined with topical injection of CSS was superior to intravenous or topical injection of CSS alone in reducing perioperative blood loss. Cite this article: Bone Joint Res 2021;10(6):354–362

Background. The reductions of perioperative blood loss and inflammatory response are important in total knee arthroplasty. Tranexamic acid reduced blood loss and the inflammatory response in several studies. However, the effect of epinephrine administration plus tranexamic acid has not been intensively investigated, to our knowledge. In this study, we evaluated whether the combined administration of low-dose epinephrine plus tranexamic acid reduced perioperative blood loss or inflammatory response further compared with tranexamic acid alone. Methods. This randomized placebo-controlled trial consisted of 179 consecutive patients who underwent primary total knee arthroplasty. Patients were randomized into 3 interventions: Group IV received intravenous low-dose epinephrine plus tranexamic acid, Group TP received topical diluted epinephrine plus tranexamic acid, and Group CT received tranexamic acid alone. The primary outcome was perioperative blood loss on postoperative day 1. Secondary outcomes included perioperative blood loss on postoperative day 3, coagulation and fibrinolysis parameters (measured by thromboelastography), inflammatory cytokine levels, transfusion values (rate and volume), thromboembolic complications, length of hospital stay, wound score, range of motion, and Hospital for Special Surgery (HSS) score. Results. The mean calculated total blood loss (and standard deviation) in Group IV was 348.1 ± 158.2 mL on postoperative day 1 and 458.0 ± 183.4 mL on postoperative day 3, which were significantly reduced (p < 0.05) compared with Group TP at 420.5 ± 188.4 mL on postoperative day 1 and 531.1 ± 231.4 mL on postoperative day 3 and Group CT at 520.4 ± 228.4 mL on postoperative day 1 and 633.7 ± 237.3 mL on postoperative day 3. Intravenous low-dose epinephrine exhibited a net anti-inflammatory activity in total knee arthroplasty and did not induce an obvious hypercoagulable status. Transfusion values were significantly (p=0.023 and 0.032) reduced in Group IV, but no significant differences were observed in the incidence of thromboembolic complications, wound score, range of motion, and HSS score among the 3 groups (p > 0.05). Conclusions. The combined administration of low-dose epinephrine and tranexamic acid demonstrated an increased effect in reducing perioperative blood loss and the inflammatory response compared with tranexamic acid alone, with no apparent increased incidence of thromboembolic and other complications

Aims. The aim of this study was to examine whether tourniquet use can improve perioperative blood loss, early function recovery, and pain after primary total knee arthroplasty (TKA) in the setting of multiple-dose intravenous tranexamic acid. Methods. This was a prospective, randomized clinical trial including 180 patients undergoing TKA with multiple doses of intravenous tranexamic acid. One group was treated with a tourniquet during the entire procedure, the second group received a tourniquet during cementing, and the third group did not receive a tourniquet. All patients received the same protocol of intravenous tranexamic acid (20 mg/kg) before skin incision, and three and six hours later (10 mg/kg). The primary outcome measure was perioperative blood loss. Secondary outcome measures were creatine kinase (CK), CRP, interleukin-6 (IL-6), visual analogue scale (VAS) pain score, limb swelling ratio, quadriceps strength, straight leg raising, range of motion (ROM), American Knee Society Score (KSS), and adverse events. Results. The mean total blood loss was lowest in the no-tourniquet group at 867.32 ml (SD 201.11), increased in the limited-tourniquet group at 1024.35 ml (SD 176.35), and was highest in the tourniquet group at 1,213.00 ml (SD 211.48). The hidden blood loss was lowest in the no-tourniquet group (both p < 0.001). There was less mean intraoperative blood loss in the tourniquet group (77.48 ml (SD 24.82)) than in the limited-tourniquet group (137.04 ml (SD 26.96)) and the no-tourniquet group (212.99 ml (SD 56.35); both p < 0.001). Patients in the tourniquet group showed significantly higher levels of muscle damage and inflammation biomarkers such as CK, CRP, and IL-6 than the other two groups (p < 0.05). Outcomes for VAS pain scores, limb swelling ratio, quadriceps strength, straight leg raising, ROM, and KSS were significantly better in the no-tourniquet group at three weeks postoperatively (p < 0.05), but there were no significant differences at three months. No significant differences were observed among the three groups with respect to transfusion rate, thrombotic events, or the length of hospital stay. Conclusion. Patients who underwent TKA with multiple doses of intravenous tranexamic acid but without a tourniquet presented lower total blood loss and hidden blood loss, and they showed less postoperative inflammation reaction, less muscle damage, lower VAS pain score, and better early knee function. Our results argue for not using a tourniquet during TKA. Cite this article: Bone Joint Res 2020;9(6):322–332

Aims. Antifibrinolytic agents, including tranexamic acid (TXA) and epsilon-aminocaproic acid (EACA), have been shown to be safe and effective for decreasing perioperative blood loss and transfusion following total hip arthroplasty (THA) and total knee arthroplasty (TKA). However, there are few prospective studies that directly compare these agents. The purpose of this study was to compare the benefits of intraoperative intravenous TXA with EACA. Patients and Methods. A total of 235 patients (90 THA and 145 TKA) were enrolled in this prospective, randomized controlled trial at a single tertiary-care referral centre. In the THA cohort, 53.3% of the patients were female with a median age of 59.8 years (interquartile range (IQR) 53.3 to 68.1). In the TKA cohort, 63.4% of the patients were female with a median age of 65.1 years (IQR 59.4 to 69.5). Patients received either TXA (n = 119) or EACA (n = 116) in two doses intraoperatively. The primary outcome measures included change in haemoglobin level and blood volume, postoperative drainage, and rate of transfusion. Secondary outcome measures included postoperative complications, cost, and length of stay (LOS). Results. TKA patients who received EACA had greater drainage (median 320 ml (IQR 185 to 420) vs 158 ml (IQR 110 to 238); p < 0.001), increased loss of blood volume (891 ml (IQR 612 to 1203) vs 661 ml (IQR 514 to 980); p = 0.014), and increased haemoglobin change from the preoperative level (2.1 ml (IQR 1.7 to 2.8) vs 1.9 ml (IQR 1.2 to 2.4); p = 0.016) compared with patients who received TXA. For the THA cohort, no statistically significant differences were observed in any haematological outcome measure. One patient in the EACA group required transfusion. No patient in the TXA group required transfusion. There were no statistically significant differences in number or type of postoperative complications or LOS for either THA or TKA patients regardless of whether they received TXA or EACA. Conclusion. For hip and knee arthroplasty procedures, EACA is associated with increased perioperative blood loss compared with TXA. However, there is no significant difference in transfusion rate. While further prospective studies are needed to compare the efficacy of each agent, we currently recommend orthopaedic surgeons to select their antifibrinolytic based on cost and regional availability. Cite this article: Bone Joint J 2019;101-B:1093–1099

Introduction. Bilateral total knee arthroplasty (TKA) results in substantial perioperative blood loss with increased morbidity. Tranexamic acid (TXA) administration in either intravenous or topical form has been found to be effective in reducing perioperative blood loss. The objective of the present study was to compare the efficacy of topical versus intravenous TXA in reducing perioperative blood loss. Methods. Prospective, randomized, double-blinded clinical trial was carried out on 70 patients undergoing bilateral TKA, who were divided into two groups. Group I received equivalent dose of TXA intravenously 30 minutes prior to deflation of tourniquet of first knee and another dose repeated after 2 hours. Group 2 received topical TXA in the dose of 15mg/kg dissolved in100 ml of normal saline which was applied into the joint for 10 minutes at the end of implant insertion. Outcome measures were total blood loss as (calculated from the difference between preoperative and postoperative day3 haemoglobin (Hb) or Hb prior to transfusion), total drain output and amount of blood transfusion. Results. Perioperative blood loss in group 2 (561.42 ± 248.99) was reduced significantly as compared to group 1 (1037.04 ±506.650) with a p-value of <0.001. The postoperative Hb in group 2 (10.30± 1.11) was also significantly higher as compared to group 1(9.66±1.47) with a p-value of <0.001. Total drain output in group 2 (269.14± 120.98) was significantly reduced as compared to group 1(574.14± 269.03) with a p-value of <0.001. There were no reports of deep vein thrombosis or pulmonary embolism in either group. Conclusion. Topical application of tranexamic acid significantly decreases the blood loss in bilateral total knee arthroplasty as compared to intravenous administration, with a mean reduction by about 45% with respect to inravenous group

Introduction: This is a retrospective study of the effectiveness of Amicar in decreasing perioperative blood loss and the need for transfusion in same-day anterior (ASF) and posterior spinal fusion (PSF) with segmental spinal instrumentation (SSI) in idiopathic scoliosis. Preliminary prospective, prospective randomized double-blind and fibrinogen studies have demonstrated Amicar to be effective in decreasing perioperative blood loss in idiopathic scoliosis surgery. Increased fibrinogen secretion is a possible explanation. Methods. Amicar is administered at 100mg/kg over 15 min not to exceed 5 grams at anesthesia induction. Maintenance is 10mg/kg/hr until wound closure. There were three study groups: Group 1, (n=15), no Amicar; Group 2, (n=27), Amicar for the PSF only; and Group 3, (n=16), Amicar for both ASF and PSF. Results. The total perioperative blood loss (estimated intraoperative blood loss for the ASF and PSF procedures, measured suction drainage and measured chest tube drainage) and the transfusion (autologous and bank blood) requirements were: Group 1, 3807±105ml and 3.1±1.5 units; Group 2 2080±659ml and 1.9±0.9 units; and Group 3 2183±851ml and 1.0±0.8 units. Conclusions. Amicar appears highly effective in decreasing perioperative blood loss and transfusion requirements in same-day ASF, PSF, with SSI in idiopathic scoliosis. This results in less preoperative autologous blood donation, blood transfusion, costs, and potential transfusion-related complications. It appears to be most effective in decreasing intraoperative PSF blood loss and chest tube drainage. It had no effect during the ASF. We now recommend that it be used for the posterior procedure only

Abstract. Introduction. In patients with bilateral unicompartmental knee osteoarthritis, simultaneous bilateral surgery is cost effective, with both patient-specific and wider socioeconomic benefits. There are concerns however regarding higher complication rates with bilateral knee surgery. This study compares simultaneous bilateral unicompartmental knee arthroplasty (UKA), to single side UKA in terms of complications and outcomes. Methodology. This is a retrospective case-control study of single side medial UKA patients (controls) and simultaneous bilateral medial UKA patients (cases). All patients underwent surgery between 2018 and 2022 by a single surgeon. The two cohorts were compared for perioperative blood loss (PBL), length of stay (LOS), complications (infections, blood clots, wound problems), Oxford Knee Score improvement (OKS) and revision surgery, with a follow-up period of up to 5 years. Results. 64 patients were followed up comprising 55 controls and 9 cases. Average length of stay for controls was 1.55 days and 2.22 days for cases (p=0.03). Average haemoglobin drop was 7.5g/l in controls and 12.8g/l in cases (p=0.04). The OKS improvement was comparable in both groups (p=0.95) with no complications and no revision surgery in either group. Conclusion. The statistically significant differences in PBL and LOS were not clinically relevant. There were no blood transfusions and postoperative haemoglobin was within normal range in more than 60% of cases. Simultaneous bilateral unicompartmental knee arthroplasty is a financially favourable and safe option for patients with bilateral knee medial unicompartmental osteoarthritis

Aims. Cementless primary total hip arthroplasty (THA) is associated with risks of bleeding and thromboembolism. Anticoagulants are effective as venous thromboprophylaxis, but with an increased risk of bleeding. Tranexamic acid (TXA) is an efficient antifibrinolytic agent, but the mode and timing of its administration remain controversial. This study aimed to determine whether two intravenous (IV) TXA regimens (a three-hour two-dose (short-TXA) and 11-hour four-dose (long-TXA)) were more effective than placebo in reducing perioperative real blood loss (RBL, between baseline and day 3 postoperatively) in patients undergoing THA who receive rivaroxaban as thromboprophylaxis. The secondary aim was to assess the non-inferiority of the reduction of blood loss of the short protocol versus the long protocol. Patients and Methods. A multicentre, prospective, randomized, double-blind, placebo-controlled trial was undertaken involving 229 patients undergoing primary cementless THA using a posterior approach, whose extended rivaroxaban thromboprophylaxis started on the day of surgery. There were 98 male and 131 female patients, with a mean age of 65.5 years (32 to 91). The primary outcome, perioperative RBL, was evaluated at 72 hours postoperatively. The efficacy of short- and long-TXA protocols in the reduction of perioperative RBL was compared with a placebo group. Results. TXA significantly reduced perioperative blood loss compared with placebo (p < 0.001); the mean differences were 525.3 ml (short-TXA vs placebo) and 550.1 ml (long-TXA vs placebo). No venous or arterial thromboembolic complications were reported. The upper boundary of the 95% confidence interval, when comparing short and long protocols, was below the pre-specified margin of non-inferiority (p = 0.027). Conclusion. In patients undergoing primary cementless THA, using a posterior approach, who are treated with rivaroxaban for thromboembolic prophylaxis, short- and long-TXA IV protocols are significantly more effective than placebo in reducing perioperative RBL, without any thromboembolic complications. Non-inferiority of a short- versus a long-TXA protocol in reducing perioperative RBL was supported in a secondary analysis

Our objective was to conduct a systematic review and meta-analysis, comparing differences in clinical outcomes between either autologous or synthetic bone grafts in the operative management of tibial plateau fractures: a traumatic pattern of injury, associated with poor long-term functional prognosis. A structured search of MEDLINE, EMBASE, The Bone & Joint and CENTRAL databases from inception until 07/28/2021 was performed. Randomised, controlled, clinical trials that compared autologous and synthetic bone grafts in tibial plateau fractures were included. Preclinical studies, clinical studies in paediatric patients, pathological fractures, fracture non-union or chondral defects were excluded. Outcome data was assessed using the Risk of Bias 2 (ROB2) framework and synthesised in random-effect meta-analysis. Preferred Reported Items for Systematic Review and Meta-Analysis guidance was followed throughout. Six comparable studies involving 352 patients were identified from 3,078 records. Following ROB2 assessment, five studies (337 patients) were eligible for meta-analysis. Within these studies, more complex tibia plateau fracture patterns (Schatzker IV-VI) were predominant. Primary outcomes showed non-significant reductions in articular depression at immediate postoperative (mean difference −0.45mm, p=0.25, 95% confidence interval (95%CI): −1.21-0.31mm, I. 2. =0%) and long-term (>6 months, standard mean difference −0.56, p=0.09, 95%CI: −1.20-0.08, I. 2. =73%) follow-up in synthetic bone grafts. Secondary outcomes included mechanical alignment, limb functionality, defect site pain, occurrence of surgical site infections, secondary surgery, perioperative blood loss, and duration of surgery. Blood loss was lower (90.08ml, p<0.001, 95%CI: 41.49-138.67ml, I. 2. =0%) and surgery was shorter (16.17minutes, p=0.04, 95%CI: 0.39-31.94minutes, I. 2. =63%) in synthetic treatment groups. All other secondary measures were statistically comparable. Our findings supersede previous literature, demonstrating that synthetic bone grafts are non-inferior to autologous bone grafts, despite their perceived disadvantages (e.g. being biologically inert). In conclusion, surgeons should consider synthetic bone grafts when optimising peri-operative patient morbidity, particularly in complex tibial plateau fractures, where this work is most applicable

Introduction. Hemophilia arthropathy often occurs in the ankle, knee and elbow. In contrast, hemophilic arthropathy in the hip is rare. We report short-term results of total hip arthroplasty (THA) in patients with hemophilia. Method. Four primary THAs performed in four hemophilic patients from 2007 to 2015 were reviewed retrospectively. Two patients underwent cementless THA, and two patients had cemented THA. All patients had hemophilia A, and clotting factor replacement was performed perioperatively. Blood loss, surgery duration, complications, pre- and post-operative range of motion, and the pre- and post-operative Japanese Orthopedic Association (JOA) score were assessed. Results. Mean age at time of surgery was 54.8 years (range 33–74 years). Mean duration of follow-up was 29.8 months (range 3–60 months). Mean perioperative blood loss was 798 ml (range 620–953 ml). No infection occurred. Mean flexion improved from 63.8° preoperatively (range 30–95°) to 83.8° postoperatively (range 60–95°). Mean abduction improved from 8.8° preoperatively (range 0–20°) to 25° postoperatively (range 10–40°). The mean JOA score improved from 47.5 preoperatively (range 35–57) to 87.5 postoperatively (range 67–100). Conclusion. THAs in patients with hemophilia can be successful and result in pain relief and functional improvement, as long as clotting factor replacement is performed adequately

The management of autologous blood aims at reducing the need for allogenic transfusion. Blood requirement (autologous and/or allogenic) will depend on the pre-operative red blood cell stock and on the perioperative blood loss. The red cell stock is related to body weight and preoperative haemoglobin (haematocrit) level; it can be calculated accurately, whereas the perioperative blood loss (external and occult) is variable and unpredictable. Preoperative donation of autologous blood, as well as intraoperative and/or postoperative recuperation and reinfusion of shed blood decrease the risk for allogenic transfusion in total hip replacement (THR) and total knee replacement (TKR) surgery. However, their efficiency and cost effectiveness are not optimal when applied to unselected patients. Up to 50% of the predonated units of autologous blood are wasted after THR and THK surgery if patients have not been specifically selected to predonate blood. In hip surgery the volume reinfused after intraoperative blood recuperation obviously depends on intraoperative bleeding; it averages 500 ml in a hip revision operation. In TKR (with a tourniquet) the volume reinfused after postoperative recuperation depends on the amount of blood drained in the immediate postoperative period, which reflects both the amount of bleeding and the efficiency of the drainage. On average, 500 ml of shed blood with a haematocrit of 35% is reinfused, which increases the haemoglobin level by 1.0 gr/dl on average. The efficiency of this technique is unpredictable, with a wide dispersion of individual values (standard deviation: 208 ml) for the volumes reinfused. However, in patients with a body weight of 70 kg or less, the increase in haemoglobin level was more predictable and averaged 1.23 gr/dl. In order to improve the efficiency of these two techniques (preoperative autologous blood donation and recuperation/reinfusion of shed blood), patients need to be targeted, taking into account:. - the calculated preoperative (day before surgery) red blood cell stock and the number of units of predonated blood,. - the lowest postoperative haemoglobin and haematocrit level clinically tolerable for that specific patient,. - the expected perioperative blood loss, which depends on such factors as duration of surgery, anticoagulant administration, use of a tourniquet,etc). As a general rule, a haemoglobin level < 13 gr/dl, age > 65 years and weight < 70 kg all increase the risk to require autologous or allogenic blood transfusion, and would justify planning predonation of blood and/or recuperation/reinfusion of shed blood

Abstract. Objectives. to evaluate the efficacy and safety of topically applied tranexamic acid (TXA) in thoracolumbar spinal tuberculosis surgery, posterior approach. Methods. Thoracolumbar spine tuberculosis patients who requiring debridement, pedicle screw fixation and fusion surgery were divided into two groups. In the TXA group (n=50), the wound surface was soaked with TXA (1 g in 100 mL saline solution) for 3 minutes after exposure, after decompression, and before wound closure, and in the control group (n=116) using only saline. Intraoperative blood loss, drain volume 48 hours after surgery, amount of blood transfusion, transfusion rate, the haemoglobin, haematocrit after the surgery, the difference between them before and after the surgery, incision infection and the incidence of deep vein thrombosis between the two groups. Results. EBL for the control group was 783.33±332.71 mL and for intervention group 410.57±189.72 mL (p<0.001). The operative time for control group was 3.24±0.38 hours and for intervention group 2.99±0.79 hours (p<0.695). Hemovac drainage on days1 and 2 for control group was 167.10±53.83mL and 99.33±37.5 mL, respectively, and for intervention group 107.03±44.37mL and 53.38±21.99mL, respectively (p<0.001). The length of stay was significantly shorter in the intervention group (4.8±1.1 days) compared to control group (7.0±2.3 days). There was bo different in incision side infection and DVT. Conclusions. Topical TXA is a viable, cost-effective method of decreasing perioperative blood loss in major spine surgery with fewer overall complications than other methods. Further studies are required to find the ideal dosage and timing